- Home
- AU vs ROIV Comparison
AU vs ROIV Comparison
Compare AU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- ROIV
- Stock Information
- Founded
- AU 1944
- ROIV 2014
- Country
- AU United States
- ROIV United Kingdom
- Employees
- AU N/A
- ROIV N/A
- Industry
- AU Precious Metals
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- AU Basic Materials
- ROIV Health Care
- Exchange
- AU Nasdaq
- ROIV Nasdaq
- Market Cap
- AU 18.3B
- ROIV 7.8B
- IPO Year
- AU 1972
- ROIV N/A
- Fundamental
- Price
- AU $45.91
- ROIV $10.95
- Analyst Decision
- AU Buy
- ROIV Buy
- Analyst Count
- AU 6
- ROIV 4
- Target Price
- AU $43.42
- ROIV $17.50
- AVG Volume (30 Days)
- AU 4.8M
- ROIV 6.7M
- Earning Date
- AU 08-05-2025
- ROIV 08-07-2025
- Dividend Yield
- AU 1.09%
- ROIV N/A
- EPS Growth
- AU N/A
- ROIV N/A
- EPS
- AU 3.06
- ROIV N/A
- Revenue
- AU $6,585,000,000.00
- ROIV $29,053,000.00
- Revenue This Year
- AU $50.01
- ROIV $2.64
- Revenue Next Year
- AU N/A
- ROIV $378.09
- P/E Ratio
- AU $14.87
- ROIV N/A
- Revenue Growth
- AU 39.37
- ROIV N/A
- 52 Week Low
- AU $22.45
- ROIV $8.73
- 52 Week High
- AU $51.11
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- AU 52.76
- ROIV 48.29
- Support Level
- AU $43.44
- ROIV $11.32
- Resistance Level
- AU $49.31
- ROIV $11.82
- Average True Range (ATR)
- AU 1.22
- ROIV 0.33
- MACD
- AU -0.48
- ROIV -0.03
- Stochastic Oscillator
- AU 42.11
- ROIV 30.27
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.